Back

Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Cardiac amyloidosis (1) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Andre Martins

Leiria Hospital Centre, Leiria (Portugal)

9 More presentations in this session

Presentation thumbnail
Discussant - Cardiac amyloidosis (1)
Presentation thumbnail
The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and follow-up outcomes of patients with wild-type transthyretin amyloidosis: comparison of the pre- and post-bone scintigraphy eras in a Latin American center.
Miss P. Domenech (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy
Doctor M. Maurer (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Cardiac amyloidosis (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Multimodality artificial intelligence-based major adverse cardiovascular events prediction in transthyretin amyloid cardiomyopathy patients
thumbnail
Congress Presentation
The value of left atrio-ventricular coupling index (LACI) in transthyretin amyloidosis: insights from a cohort analysis
thumbnail
Congress Session
Novelties in amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources